Answers are grounded in this paper and cite their sources.
Porcine reproductive and respiratory syndrome (PRRS) is an economically important disease that endangers the global pig industry and is caused by porcine reproductive and respiratory syndrome virus (PRRSV). Although previous studies have reported that PRRSV hijacks autophagy to facilitate its replication, the role of selective autophagy in PRRSV propagation remains largely unclear. Here, we identified the autophagic cargo receptor SQSTM1 as a novel host restriction factor against PRRSV. SQSTM1 overexpression significantly suppresses PRRSV replication, while SQSTM1 knockdown promotes viral proliferation. Moreover, SQSTM1 overexpression enhances the autophagic degradation of multiple PRRSV proteins, including Nsp5, Nsp12, GP4, and GP5. We further selected GP4 and GP5 as target proteins to explore the molecular mechanism by which SQSTM1 degrades PRRSV proteins. SQSTM1 promotes the trafficking of GP4 to LAMP2-positive lysosomes for autophagy‑lysosome-dependent degradation. SQSTM1 directly interacts with both GP4 and GP5, and recruits the host E3 ubiquitin ligase TRAF6 to enhance the polyubiquitination of these two viral proteins. Both the LC3-interacting region (LIR) and ubiquitin-associated (UBA) domains of SQSTM1 are required for SQSTM1-mediated inhibition of PRRSV replication. Further mechanistic validation showed that TRAF6 mediates K63-linked polyubiquitination of GP4 at the K115 residue and GP5 at the K59 residue. These ubiquitination modifications are indispensable for the binding of GP4/GP5 to SQSTM1 and their subsequent autophagic degradation. TRAF6 knockdown abrogates SQSTM1-induced degradation of PRRSV Nsp5, Nsp12, GP4, and GP5, and eliminates the antiviral activity of SQSTM1, indicating that SQSTM1 and TRAF6 synergistically degrade viral proteins and constrain PRRSV replication. The present study demonstrates the critical role of selective autophagy in host defense against PRRSV infection. These findings provide novel insights for the development of targeted anti-PRRSV drugs and vaccines.
No takes yet. Share an insight, caveat, or question.
Duan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: